CTL_NN
recognition_NN
of_IN
an_DT
altered_JJ
peptide_NN
associated_VBN
with_IN
asparagine_NN
bond_NN
rearrangement_NN
._.

Implications_NNS
for_IN
immunity_NN
and_CC
vaccine_NN
design_NN
._.

The_DT
extent_NN
to_TO
which_WDT
peptides_NNS
containing_VBG
chemically_RB
and_CC
post-translationally_RB
modified_VBN
amino_NN
acid_NN
side_JJ
chains_NNS
are_VBP
recognized_VBN
by_IN
primed_VBN
CTL_NN
has_VBZ
not_RB
been_VBN
clearly_RB
defined_VBN
._.

We_PRP
report_VBP
on_IN
the_DT
CTL_NN
recognition_NN
of_IN
a_DT
MHC_NN
class_NN
I-restricted_JJ
peptide_NN
containing_VBG
a_DT
cyclized_JJ
asparagine_NN
-LRB-_-LRB-
succinimide_NN
-RRB-_-RRB-
residue_NN
._.

This_DT
modification_NN
of_IN
the_DT
asparagine_NN
side_JJ
chain_NN
is_VBZ
a_DT
common_JJ
intermediate_JJ
structure_NN
during_IN
deamidation_NN
,_,
isomerization_NN
,_,
and_CC
bond_NN
rearrangements_NNS
of_IN
amide-containing_JJ
amino_NN
acids_NNS
and_CC
also_RB
occurs_VBZ
as_IN
a_DT
side_JJ
reaction_NN
in_IN
peptide_NN
synthesis_NN
._.

The_DT
CTL_NN
specifically_RB
recognized_VBD
the_DT
succinimide-containing_JJ
peptide_NN
showing_VBG
only_RB
weak_JJ
cross-reactivity_NN
at_IN
high_JJ
concentrations_NNS
of_IN
the_DT
parent_JJ
peptide_NN
containing_VBG
unmodified_JJ
asparagine_NN
._.

Similarly_RB
,_,
CTL_NN
raised_VBN
against_IN
the_DT
parent_JJ
peptide_NN
did_VBD
not_RB
recognize_VB
the_DT
succinimide_JJ
derivative_NN
of_IN
this_DT
peptide_NN
._.

Naturally_RB
processed_VBN
forms_NNS
of_IN
these_DT
structures_NNS
are_VBP
likely_JJ
to_TO
occur_VB
given_JJ
the_DT
importance_NN
and_CC
frequency_NN
of_IN
deamidation_NN
both_CC
in_FW
vitro_FW
and_CC
in_FW
vivo_FW
._.

Moreover_RB
,_,
since_IN
succinimide_JJ
intermediates_NNS
of_IN
deamidated_VBN
peptides_NNS
can_MD
occasionally_RB
be_VB
very_RB
stable_JJ
,_,
these_DT
peptides_NNS
have_VBP
the_DT
potential_NN
to_TO
act_VB
as_IN
altered_JJ
self-Ags_NNS
with_IN
significant_JJ
implications_NNS
for_IN
autoimmunity_NN
._.

In_IN
addition_NN
,_,
unwanted_JJ
and_CC
potentially_RB
hazardous_JJ
specificities_NNS
may_MD
be_VB
elicited_VBN
when_WRB
using_VBG
synthetic_JJ
peptides_NNS
in_IN
subunit_NN
vaccines_NNS
in_IN
which_WDT
succinimide_JJ
residues_NNS
may_MD
form_VB
spontaneously_RB
during_IN
storage_NN
or_CC
chemical_JJ
synthesis_NN
._.

